Recent Updates
Recently added Catalysts
ONCY Positive Sentiment

Oncolytics Biotech® to Participate in a Fireside Chat at the H.C. Wainwright 25th Annual Global Investment Conference

Key Takeaway: Oncolytics Biotech Inc. announced that CEO Dr. Matt Coffey will speak at the H.C. Wainwright 25th Annual Global Investment Conference taking place from September 11-13, 2023, in New York. The company will also participate in one-on-one investor meetings and provide a live webcast of the presentation. Oncolytics is known for developing pelareorep, an immunotherapeutic agent aimed at treating various cancers. This event is expected to increase the company's engagement with potential investors.
Price reaction · baseline $2.35 (2023-09-05 close) · hit after-hours · 1 other ONCY headline(s) in the window, move may be shared
day 0 close · peak
+2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Participation in a prominent investment conference enhances visibility.
  • Opportunity for one-on-one investor meetings may attract interest in the company.
  • Showcases company leadership with CEO's involvement in the event.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck

Full Press Release Details

SAN DIEGO and CALGARY, AB, Sept. 6, 2023 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced that Chief Executive Officer Dr. Matt Coffey will participate in a fireside chat at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place September 11-13, 2023 at the Lotte New York Palace Hotel in New York, NY. Additional details on the fireside chat can be found below.
Date: Tuesday, September 12, 2023
Location: Lotte New York Palace Hotel, Adams Room 4th Floor
Webcast Link: Available by clicking here
Company management will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please submit a request on the conference website, contact your H.C. Wainwright representative, or email [email protected].
A live webcast of the Company's presentation will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.
Pelareorep has demonstrated synergies with multiple approved oncology treatments. Oncolytics is currently conducting and planning combination clinical trials with pelareorep in solid and hematological malignancies as it advances towards registrational studies in metastatic breast cancer and pancreatic cancer. For further information, please visit: www.oncolyticsbiotech.com.
Investor Relations for Oncolytics
Director of IR & Communication

Frequently Asked Questions

When will Oncolytics Biotech participate in the Global Investment Conference?

Oncolytics Biotech will participate in the conference on September 12, 2023.

Where is the H.C. Wainwright conference being held?

The conference will be held at the Lotte New York Palace Hotel.

What is pelareorep developed by Oncolytics Biotech?

Pelareorep is an immunotherapeutic agent that enhances anti-cancer immune responses.

How can investors request meetings with Oncolytics management?

Investors can schedule meetings via the conference website or by email.

Will Oncolytics' presentation be available online?

Yes, a live webcast will be available on their Investor Relations page.

Last updated: Sep 6, 2023